scispace - formally typeset
H

Hyo Jung Park

Researcher at Samsung Medical Center

Publications -  48
Citations -  398

Hyo Jung Park is an academic researcher from Samsung Medical Center. The author has contributed to research in topics: Radiation therapy & Chemoradiotherapy. The author has an hindex of 11, co-authored 48 publications receiving 291 citations.

Papers
More filters
Journal ArticleDOI

Reversal of Intestinal Failure-Associated Liver Disease by Switching From a Combination Lipid Emulsion Containing Fish Oil to Fish Oil Monotherapy.

TL;DR: Report of 2 cases of IFALD reversed by switching from a combination lipid emulsion containing fish oil to fish oil monotherapy (Omegaven; Fresenius Kabi Austria Gmbh, Graz, Austria).
Journal ArticleDOI

Trough Concentrations of Vancomycin in Patients Undergoing Extracorporeal Membrane Oxygenation.

TL;DR: The current dosing strategy of the institution for vancomycin in the ICU was not sufficient to achieve the target trough in the initial period in most patients receiving ECMO, and the elimination rate was similar with population parameter of non ECMO patients.
Journal ArticleDOI

Comparison of acute skin reaction following morning versus late afternoon radiotherapy in patients with breast cancer who have undergone curative surgical resection

TL;DR: RT in late afternoon was associated with increased Grade 2 or more skin reaction after RT for breast cancer patients, but treatment outcomes did not differ according to the time of RT.
Journal ArticleDOI

Association between BRCA Mutation Status, Pathological Findings, and Magnetic Resonance Imaging Features in Patients with Breast Cancer at Risk for the Mutation

TL;DR: Rim enhancement was frequently seen on MRI scans of high-grade cancers and in the TN phenotype, and it was a significant predictor of disease recurrence, however, a direct association with BRCA mutations was not observed.
Journal ArticleDOI

Evaluation of risk factors for vancomycin-induced nephrotoxicity

TL;DR: It is suggested that higher vancomycin trough levels and intensive care unit (ICU) residence might be associated with a greater risk for VAN, and more careful monitoring of vancomYcin serum trough Levels and patient status might facilitate the timely prevention of VAN.